Dupixent phase 3 results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis

Press/Media

Period	25 Oct 2023

Media coverage

Title	Dupixent phase 3 results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis
Media name/outlet	PharmaBiz
Country/Territory	India
Date	25/10/23
URL	www.pharmabiz.com/NewsDetails.aspx?aid=163206&sid=2
Persons	Mirna Chehade